A new analysis commissioned by the Rare Disease Company Coalition (RDCC) and conducted by Charles River Associates (CRA) finds that U.S. adoption of a Most Favored Nation model would risk undermining the nation’s progress in rare disease innovation and delaying patient access to life-changing therapies. As a result, the CRA analysis concludes that excluding orphan drugs from these pricing measures is crucial to protecting patient access and innovation.